花旗:升H&H國際(1112.HK)目標價至41港元 評級“買入”
花旗發表研究報告,引述H&H國際(01112.HK)管理層表示,去年第四季旗下嬰幼兒及成人營養及護理用品業務均出現復甦,相信主因階段性影響和新產品推出。管理層更目標今年兩大業務收入將錄雙位數增長(相對於2019年嬰幼兒產品料升15%,而成人產品則跌5%),且預計今年EBITDA利潤率輕微回升。
該行下調其2019年核心利潤預測6%,以反映較高研發支出及融資成本預期,但大致維持今年度盈利預測,因此維持其“買入”評級,指估值不高,今年有望復甦,目標價更由35.8港元升至41港元,但風險是市場對其預期過高。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.